Skip to main content

CANVAS: CANagliflozin cardioVascular Assessment Study

Updated: 8/14/21 12:00 pmPublished: 2/28/10 Identifier: NCT01032629

The CANVAS study is designed to examine the cardiovascular safety of canagliflozin, a new drug in development in a class called SGLT2 inhibitors. SGLT2 inhibitors allow the kidneys to excrete glucose instead of conserving it in the bloodstream, thus lowering blood sugar. In addition to limiting hyperglycemia, this drug class has shown significant weight loss in clinical trials, which could lead to further benefits in treating type 2 diabetes. Currently, there are no SGLT2 inhibitors approved by the FDA, although canagliflozin is one of several currently in clinical trials. Participants in this study will be randomized to take one pill per day that will contain one of the following: a placebo, 100mg canagliflozin, or 300 mg canagliflozin. The length of the study is expected to be four years, during which study participants will be monitored for any major cardiovascular problems. To be eligible for this study, you must have type 2 diabetes, a high risk for cardiovascular disease, and an A1c between 7.0% and 10.5%. You must also be aged 30 or older. For more information on how to participate, you can go here or you can email [email protected] with any questions.



What do you think?